VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRXFree Report) in a research note published on Sunday. The firm issued a sell rating on the stock.

Separately, Cantor Fitzgerald reiterated an overweight rating and set a $2.50 target price on shares of VolitionRx in a report on Thursday, May 16th.

Check Out Our Latest Research Report on VolitionRx

VolitionRx Price Performance

VNRX opened at $0.63 on Friday. The stock has a market capitalization of $52.58 million, a price-to-earnings ratio of -1.38 and a beta of 1.14. The business has a 50-day moving average of $0.71 and a two-hundred day moving average of $0.83. VolitionRx has a 12 month low of $0.55 and a 12 month high of $1.55.

VolitionRx (NYSE:VNRXGet Free Report) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.27 million. Equities research analysts anticipate that VolitionRx will post -0.31 earnings per share for the current year.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new stake in VolitionRx Limited (NYSE:VNRXFree Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned approximately 0.19% of VolitionRx as of its most recent SEC filing. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

Read More

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.